Zydus Cadila has started enrolling and dosing participants in India for the Phase 3 clinical trial of its three-dose COVID-19 vaccine ZyCoV-D, according to reports. The trials are expected to take place across four cities - Surat, Nashik, Jaipur and Ahmedabad. Zydus Cadila received DCGI's approval earlier this month to initiate Phase 3 trials in 26,000 Indian participants.